Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aligos Therapeutics (Nasdaq: ALGS), a clinical stage biopharmaceutical company focusing on liver and viral diseases, has announced the granting of non-qualified stock options to newly hired employees. The Compensation Committee of the Company's Board of Directors approved these Inducement Grants on October 8, 2024, totaling 95,000 shares of the Company's stock.
Notably, Dr. Hardean Achneck, the new Chief Medical Officer, received an option to purchase 75,000 shares. These grants, made under Aligos' 2024 Employment Inducement Award Plan, comply with Nasdaq Listing Rule 5635(c)(4) and serve as an inducement for new employees. The options have an exercise price equal to the closing price of Aligos' common stock on the grant date and will vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly, subject to continued employment.
Aligos Therapeutics (Nasdaq: ALGS), una società biofarmaceutica in fase clinica focalizzata sulle malattie epatiche e virali, ha annunciato l'assegnazione di opzioni su azioni non qualificate ai nuovi dipendenti assunti. Il Comitato per la Compensazione del Consiglio di Amministrazione della Società ha approvato queste Concessioni di Induzione l'8 ottobre 2024, per un totale di 95.000 azioni della società.
In particolare, Dr. Hardean Achneck, il nuovo Direttore Medico, ha ricevuto un'opzione per acquistare 75.000 azioni. Queste concessioni, effettuate nell'ambito del 2024 Employment Inducement Award Plan di Aligos, sono conformi alla Regola di Listaggio Nasdaq 5635(c)(4) e servono come incentivo per i nuovi dipendenti. Le opzioni hanno un prezzo di esercizio pari al prezzo di chiusura delle azioni ordinarie di Aligos alla data di assegnazione e matureranno in quattro anni, con il 25% che matura al primo anniversario e il resto che matura mensilmente, soggetto a continua occupazione.
Aligos Therapeutics (Nasdaq: ALGS), una compañía biofarmacéutica en etapa clínica centrada en enfermedades del hígado y virales, ha anunciado la concesión de opciones sobre acciones no calificadas a empleados recién contratados. El Comité de Compensación de la Junta Directiva de la Compañía aprobó estas Concesiones de Inducción el 8 de octubre de 2024, totalizando 95,000 acciones de la compañía.
Notablemente, Dr. Hardean Achneck, el nuevo Director Médico, recibió una opción para comprar 75,000 acciones. Estas concesiones, realizadas bajo el 2024 Employment Inducement Award Plan de Aligos, cumplen con la Regla de Listado Nasdaq 5635(c)(4) y sirven como un incentivo para nuevos empleados. Las opciones tienen un precio de ejercicio igual al precio de cierre de las acciones comunes de Aligos en la fecha de concesión y adquirirán derechos en un período de cuatro años, con el 25% adquiriendo derechos en el primer aniversario y el resto adquiriendo derechos mensualmente, sujeto a una continuidad en el empleo.
Aligos Therapeutics(Nasdaq: ALGS)는 간 및 바이러스 질환에 집중하는 임상 단계의 생명공학 회사로, 신규 채용된 직원들에게 비자격 주식 옵션을 부여한다고 발표했습니다. 회사 이사회 보상 위원회는 2024년 10월 8일에 총 95,000주의 주식에 대한 유인 부여를 승인했습니다.
특히, Dr. Hardean Achneck 신임 최고 의료 책임자는 75,000주를 구매할 수 있는 옵션을 받았습니다. 이러한 부여는 Aligos의 2024 Employment Inducement Award Plan에 따라 이루어졌으며, Nasdaq의 상장 규칙 5635(c)(4)를 준수하고 신규 직원들에게 유인을 제공합니다. 옵션의 행사가격은 부여 당일 Aligos의 보통주 종가와 같으며, 4년에 걸쳐 권리가 부여됩니다. 첫 해에 25%의 권리가 부여되고 나머지는 매달 권리가 부여되며, 지속적인 고용이 조건입니다.
Aligos Therapeutics (Nasdaq: ALGS), une société biopharmaceutique en phase clinique axée sur les maladies du foie et virales, a annoncé l'octroi de stock-options non qualifiées à de nouveaux employés. Le comité de rémunération du conseil d'administration de la société a approuvé ces attributions d'incitation le 8 octobre 2024, pour un total de 95 000 actions de la société.
Notamment, Dr. Hardean Achneck, le nouveau directeur médical, a reçu une option d'achat de 75 000 actions. Ces attributions, effectuées dans le cadre du 2024 Employment Inducement Award Plan d'Aligos, sont conformes à la règle de cotation Nasdaq 5635(c)(4) et servent d'incitation pour les nouveaux employés. Les options ont un prix d'exercice égal au prix de clôture des actions ordinaires d'Aligos à la date d'octroi et s'acquitteront sur quatre ans, avec 25 % s'acquittant à la première annuité et le reste s'acquittant mensuellement, sous réserve d'un emploi continu.
Aligos Therapeutics (Nasdaq: ALGS), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf Leber- und Viruskrankheiten konzentriert, hat die Vergabe von nicht qualifizierten Aktienoptionen an neu eingestellte Mitarbeiter bekannt gegeben. Der Vergütungsausschuss des Vorstands der Gesellschaft genehmigte diese Induktion Zuwendungen am 8. Oktober 2024, insgesamt 95.000 Aktien der Gesellschaft.
Besonders Dr. Hardean Achneck, der neue Chief Medical Officer, erhielt eine Option zum Kauf von 75.000 Aktien. Diese Zuwendungen, die im Rahmen des 2024 Employment Inducement Award Plan von Aligos gewährt wurden, entsprechen der Nasdaq-Listing-Regel 5635(c)(4) und dienen als Anreiz für neue Mitarbeiter. Die Optionen haben einen Ausübungspreis, der dem Schlusskurs der Stammaktien von Aligos am Gewährungstag entspricht und werden über vier Jahre fällig, wobei 25% am ersten Jahrestag fällig werden und der Rest monatlich fällig wird, vorbehaltlich einer fortdauernden Beschäftigung.
- Aligos Therapeutics is attracting new talent, including a Chief Medical Officer
- The company has implemented an employee incentive program through stock options
- The issuance of new stock options may lead to potential dilution for existing shareholders
SOUTH SAN FRANCISCO, Calif., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 95,000 shares of the Company’s stock (the “Inducement Grants”) to newly hired employees on October 8, 2024 (the “Grant Date”), in connection with the commencement of employment. Included in the aggregate number is the grant of an option to purchase 75,000 shares to Dr. Hardean Achneck, in connection with the commencement of his role as Chief Medical Officer.
The Inducement Grants were granted pursuant to Aligos’ 2024 Employment Inducement Award Plan (the “Plan”) as an inducement material to entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Aligos.
The Inducement Grants have an exercise price per share equal to the closing price of Aligos’ common stock on the Grant Date. The shares subject to the Inducement Grants will vest over a four-year period, with
About Aligos
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) and viruses with high unmet medical need such as hepatitis B and coronaviruses.
For more information, please visit www.aligos.com or follow us on LinkedIn or X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding the Aligos’ mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Such forward-looking statements are subject to substantial risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical stage of development, the process of designing and conducting clinical trials and the regulatory approval processes. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2024 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
Aligos Therapeutics
Contact
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
+1 (650) 910-0427
jtarazi@aligos.com
FAQ
How many shares of stock options did Aligos Therapeutics (ALGS) grant to new employees on October 8, 2024?
Who is the new Chief Medical Officer of Aligos Therapeutics (ALGS) and how many stock options did they receive?
What is the vesting schedule for the Inducement Grants issued by Aligos Therapeutics (ALGS) on October 8, 2024?
Under which plan were the Inducement Grants issued by Aligos Therapeutics (ALGS) on October 8, 2024?
